Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
CIPLA LIMITED |
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 1,192.30 INR | -0.53% | -4.39% | +10.81% | |
| Nov. 27 | Cipla's Arm Acquires Additional 15% Stake in Joint Venture | MT |
| Nov. 24 | Selling in IT Drags Indian Equities to Close Lower on Friday | MT |
ETFs positioned on Cipla Limited
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.45% | 105 M€ | +14.40% | ||
| 1.22% | 37 M€ | +7.74% | ||
| 1.03% | 63 M€ | +6.58% | - | |
| 0.99% | 6 M€ | +6.07% | - | |
| 0.92% | 40 M€ | +3.63% | - | |
| 0.86% | 12 M€ | +2.72% | ||
| 0.83% | 91 M€ | +9.55% | - | |
| 0.79% | 2,136 M€ | +6.92% | - | |
| 0.79% | 5,572 M€ | +9.04% | ||
| 0.78% | 163 M€ | +13.36% | ||
| 0.77% | 646 M€ | +8.60% | - | |
| 0.77% | 53 M€ | +8.48% | - | |
| 0.75% | 142 M€ | +13.50% | - | |
| 0.75% | 43 M€ | +7.31% | ||
| 0.66% | 401 M€ | +12.11% | ||
| 0.65% | 317 M€ | +9.83% | - | |
| 0.64% | 42 M€ | 0.00% | - | |
| 0.64% | 258 M€ | -1.33% | - | |
| 0.63% | 16 M€ | +2.41% | - | |
| 0.56% | 31 M€ | +14.71% | ||
| 0.54% | 4 M€ | +13.42% | - | |
| 0.53% | 19 M€ | 0.00% | ||
| 0.49% | 47 M€ | 0.00% | - | |
| 0.45% | 201 M€ | +4.96% | ||
| 0.44% | 1,294 M€ | +16.49% | ||
| 0.44% | 17 M€ | +13.23% | ||
| 0.37% | 167 M€ | +10.49% | ||
| 0.33% | 61 M€ | 0.00% | - | |
| 0.32% | 300 M€ | +4.47% | - |
Cipla specializes in development, manufacturing and marketing of pharmaceutical products. The group provides prescription products and OTC medicines for the treatment of cardiovascular, ophthalmic and dermatological diseases, respiratory troubles, cancers, allergies, infections etc. Besides, Cipla develops and sells veterinary products.
Net sales by source of income break down between sale of products (96.9%) and services (3.1%).
Net sales are distributed geographically as follows: India (39.4%), the United States (18.5%), South Africa (17%) and other (25.1%).
Sector
Pharmaceuticals
Calendar
2024-02-06
- Q3 2024 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
37
Last Close Price
1,192.30INR
Average target price
1,256.70INR
Spread / Average Target
+5.40%
EPS Revisions
| 1st Jan change | Capi. (M$) | |
|---|---|---|
| +10.81% | 11 609 M $ | |
| +18.97% | 34 409 M $ | |
| +30.89% | 20 519 M $ | |
| 0.00% | 12 908 M $ | |
| -11.19% | 9 035 M $ | |
| +49.97% | 7 770 M $ | |
| -0.05% | 6 788 M $ | |
| -8.87% | 5 726 M $ | |
| +2.25% | 5 025 M $ | |
| +2.41% | 4 549 M $ |
- Stock
- Equities
- Stock Cipla Limited - NSE India Stock Exchange
- Funds and ETFs Cipla Limited